Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Cohort 1A Inclusion Criteria:
Cohort C Inclusion Criteria:
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria apply
Primary purpose
Allocation
Interventional model
Masking
1,041 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal